REGN – Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

REGN

$774.80

Name : Regeneron Pharmaceuticals, Inc.

Sector : Healthcare

Industry: Biotechnology

Mark. Cap: $81,911,709,696.00

EPSttm : 41.49

Regeneron Pharmaceuticals, Inc.

$774.80

0.28%

$2.16

REGN — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

2.41

Margin Of Safety %

-10

Put/Call OI Ratio

0.92

EPS Next Q Diff

4.14

EPS Last/This Y

1.71

EPS This/Next Y

2.66

Price

772.52

Target Price

880.65

Analyst Recom

1.61

Performance Q

-1.01

Upside

88.3%

Beta

0.41

Ticker: REGN

21 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-02	REGN	788.52	0.67	1.35	45535
2026-03-03	REGN	766.74	0.68	1.52	46144
2026-03-04	REGN	787.59	0.70	0.79	46733
2026-03-05	REGN	766.78	0.69	0.51	47232
2026-03-06	REGN	759.4	0.69	1.24	47373
2026-03-09	REGN	781.18	0.68	0.25	46202
2026-03-10	REGN	772.48	0.67	0.71	46633
2026-03-11	REGN	774.3	0.67	0.53	46750
2026-03-12	REGN	746.65	0.67	0.45	46942
2026-03-13	REGN	746.61	0.67	0.47	46942
2026-03-17	REGN	758.7	0.67	0.26	46899
2026-03-18	REGN	744.27	0.67	0.46	47103
2026-03-19	REGN	737.18	0.67	0.73	47288
2026-03-20	REGN	732.7	0.67	0.31	47372
2026-03-23	REGN	736.06	0.94	0.45	30985
2026-03-24	REGN	741.78	0.93	0.71	31456
2026-03-25	REGN	750.02	0.92	0.33	31809
2026-03-26	REGN	756.59	0.91	0.84	32043
2026-03-27	REGN	739.21	0.91	0.70	32221
2026-03-30	REGN	749.42	0.91	1.64	31636
2026-03-31	REGN	772.14	0.92	1.17	32425
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

21 items 1 of 1

21 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-03-02	REGN	791.22	11.4	-1406.3	44.69
2026-03-03	REGN	766.40	11.4	-1583.3	44.69
2026-03-04	REGN	787.56	11.2	-1344.2	44.67
2026-03-05	REGN	765.06	11.2	-1573.6	44.67
2026-03-06	REGN	759.86	11.2	-1484.4	44.67
2026-03-09	REGN	781.60	11.2	-1333.5	44.67
2026-03-10	REGN	772.33	11.1	-1505.3	44.83
2026-03-11	REGN	774.59	11.1	-1442.9	44.83
2026-03-12	REGN	746.49	10.8	-1606.1	44.83
2026-03-13	REGN	746.13	10.8	-1459.2	44.79
2026-03-17	REGN	759.05	10.8	-1444.9	44.79
2026-03-18	REGN	744.49	10.8	-1535.6	44.79
2026-03-19	REGN	737.16	10.8	-1613.9	44.79
2026-03-20	REGN	732.87	10.8	-1601.4	44.79
2026-03-23	REGN	735.97	10.8	-1559.7	44.79
2026-03-24	REGN	741.66	10.7	-1548.7	44.78
2026-03-25	REGN	749.68	10.7	-1533.5	44.78
2026-03-26	REGN	756.73	10.7	-1537.9	44.78
2026-03-27	REGN	737.71	10.7	-1676.9	44.78
2026-03-30	REGN	748.54	10.7	-1517.8	44.78
2026-03-31	REGN	772.52	10.7	-1452.7	44.78
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

21 items 1 of 1

21 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-02	REGN	-0.33	0.85	2.02
2026-03-03	REGN	-0.33	0.85	2.02
2026-03-04	REGN	-0.33	0.85	2.02
2026-03-05	REGN	-0.33	0.85	2.02
2026-03-06	REGN	-0.33	0.85	2.02
2026-03-09	REGN	-0.33	0.97	2.02
2026-03-10	REGN	-0.33	0.97	2.02
2026-03-11	REGN	-0.33	0.97	2.25
2026-03-12	REGN	-0.33	0.97	2.25
2026-03-13	REGN	-0.33	0.97	2.25
2026-03-17	REGN	-0.33	0.94	2.25
2026-03-18	REGN	-0.33	0.94	2.25
2026-03-19	REGN	-0.33	0.94	2.25
2026-03-20	REGN	-0.33	0.94	2.25
2026-03-23	REGN	-0.33	0.93	2.25
2026-03-24	REGN	-0.33	0.93	2.25
2026-03-25	REGN	-0.33	0.93	2.41
2026-03-26	REGN	-0.33	0.93	2.41
2026-03-27	REGN	-0.33	0.93	2.41
2026-03-30	REGN	-0.33	0.93	2.41
2026-03-31	REGN	-0.33	0.93	2.41
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

21 items 1 of 1

Last Quarter Act. EPS

6.57

Avg. EPS Est. Current Quarter

9.1

Avg. EPS Est. Next Quarter

10.71

Insider Transactions

-0.33

Institutional Transactions

0.93

Beta

0.41

Average Sales Estimate Current Quarter

3453

Average Sales Estimate Next Quarter

3804

Fair Value

694.57

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

36.2

Max Drawdown 5-Year %

-59.7

Target Price

880.65

P/E

18.59

Forward P/E

14.58

PEG

1.3

P/S

5.69

P/B

2.61

P/Free Cash Flow

20.01

EPS

41.56

Average EPS Est. Cur. Y

44.78

EPS Next Y. (Est.)

47.45

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

31.41

Relative Volume

0.86

Return on Equity vs Sector %

-13

Return on Equity vs Industry %

3.2

EPS 1 7Days Diff

EPS 1 30Days Diff

0.09

EBIT Estimation

-1452.7

◆ REGN Healthcare

$772.64

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

12/20

Pullback

8/25

Volume

7/15

Valuation

11/20

TP/AR

3/10

Options

2/10

RSI

55.1

Range 1M

64.5%

Sup Dist

4.1%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

9/25

Growth

11/30

Estimates

7/20

Inst/Vol

4/15

Options

4/10

EPS Yr

2.5%

EPS NY

16.7%

52W%

85.5%

💎

Long-Term Value

Quality companies, undervalued

WATCH

🟢 BUY +57.2% upside

Quality

20/30

Valuation

15/30

Growth

9/25

Stability

10/10

LT Trend

3/5

Upside

+57.2%

Quality

MoS

-10%

Regeneron Pharmaceuticals, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 15410

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company was incorporated in 1988 and is based in Tarrytown, New York.

REGN

Latest News

—

Caricamento notizie per REGN…

stock quote shares REGN – Regeneron Pharmaceuticals, Inc. Stock Price stock today

news today REGN – Regeneron Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch REGN – Regeneron Pharmaceuticals, Inc. yahoo finance google finance

stock history REGN – Regeneron Pharmaceuticals, Inc. invest stock market

stock prices REGN premarket after hours

ticker REGN fair value insiders trading

REGN – Regeneron Pharmaceuticals, Inc.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: REGN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y